LRMR Stock Forecast: Larimar Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$3.14
−2.48% on the day

The median 12-month analyst price target for Larimar Therapeutics, Inc. is $13. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$328.6M
Ticker Nerd rank
29/ 100
Median analyst target
$13
Analysts covering
11
Revenue$0.0
Operating income−$34.4M
Net income−$32.8M
Free cash flow−$44.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.0%
1M
+28.7%
YTD
−17.6%
1Y
−6.8%
From 52W high
−47.2%
From 52W low
+58.2%
$1.99
$5.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Larimar Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
29/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
67
Revisions
65
Volatility
41
Value
40
Momentum
39
Issuance
22
Quality
20
Growth
20

Accruals (67): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (20): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LRMR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LRMR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26LRMRHigh $26Median $13Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11
Buy
0
Hold
0
Sell
$5
Low
$13
Median
$26
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
17 Nov 2026WedbushMaintainsOutperform$11 → $9.00
14 Sept 2026Leerink PartnersAssumesOutperform$13
5 Aug 2026WedbushMaintainsOutperform$12 → $11
2 July 2026HC Wainwright & Co.AssumesBuy$10
30 June 2026BairdMaintainsOutperform$7.00 → $5.00
27 May 2026JP MorganInitiatesOverweight—
18 May 2026WedbushMaintainsOutperform—
20 Mar 2026WedbushMaintainsOutperform—
3 Mar 2026WedbushMaintainsOutperform—
25 Feb 2026CitigroupMaintainsBuy—
25 Feb 2026WedbushReiteratesOutperform—
2 Oct 2025OppenheimerMaintainsOutperform—
30 Sept 2025BairdMaintainsOutperform—
30 Sept 2025WedbushMaintainsOutperform—
19 Aug 2025JMP SecuritiesReiteratesMarket Outperform—
15 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
25 June 2025GuggenheimReiteratesBuy—
24 June 2025GuggenheimReiteratesBuy—
24 June 2025WedbushMaintainsOutperform—
25 Mar 2025BairdMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LRMR.

Market Radar

This page is one stock. Monday covers all of them.

LRMR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LRMR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Larimar Therapeutics, Inc. returned −6.8% against +6.9% for the S&P 500, dividends included.

LRMR vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Jan 26Apr 26Jul 26Oct 26LRMRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LRMR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
3.3×

Cheaper than 28% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−129.8%

Higher than 11% of US stocks

Return on assets
−61.7%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Larimar Therapeutics, Inc. has a market value of $328.6M and an enterprise value of $204.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$172.6M.

  • Diluted earnings per share, trailing twelve months: −$1.95.

  • Free cash flow in the twelve months to 30 June 2026: −$156.1M.

  • Shares outstanding: 103.9M.

  • Larimar Therapeutics, Inc. employs 71 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

LRMR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LRMRLarimar Therapeutics, Inc.$328.6M29
MPLTMapLight Therapeutics, Inc.$330.1M16
INOInovio Pharmaceuticals, Inc.$329.7M49
CTNMContineum Therapeutics, Inc.$336.4M32
CCCCC4 Therapeutics, Inc.$325.7M65
LYELLyell Immunopharma, Inc.$338.2M80
YDESYD Bio Ltd.$342.2M3

Take a look at LRMR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Larimar Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LRMR

What is the LRMR stock price forecast for 2026-2027?

The median 12-month analyst price target for Larimar Therapeutics, Inc. is $13, with estimates ranging from $5 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LRMR stock a buy right now?

Of the 11 analysts covering Larimar Therapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Larimar Therapeutics, Inc. 29 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LRMR?

As at 21 Nov 2026, Larimar Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (67 of 100).

Will LRMR stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts is $13, and Ticker Nerd's factor model ranks Larimar Therapeutics, Inc. 29 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LRMR stock forecast for 2030?

No analyst covering Larimar Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LRMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $26 over the next 12 months.

How has LRMR stock performed over the past year?

Larimar Therapeutics, Inc. returned -6.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Larimar Therapeutics, Inc. do?

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with an emphasis on Friedreich’s ataxia. The company’s core program is nomlabofusp, a protein replacement therapy designed to deliver frataxin inside cells and address the underlying biology of this inherited disorder.

Company

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with an emphasis on Friedreich’s ataxia. The company’s core program is nomlabofusp, a protein replacement therapy designed to deliver frataxin inside cells and address the underlying biology of this inherited disorder. Larimar’s work centers on its proprietary intracellular delivery platform, which is intended to support the development of additional therapies for rare conditions caused by missing or deficient proteins. The company operates as a focused research and development organization, advancing clinical programs and related manufacturing, development, and regulatory activities through external partners. Larimar Therapeutics is based in Bala Cynwyd, Pennsylvania, and plays a specialized role in the rare-disease biopharmaceutical market by pursuing targeted treatments for patients with limited therapeutic options.

CEO Dr. Carole S. Ben-Maimon M.D. · 71 employees · United States · https://www.larimartx.com